Literature DB >> 1756494

Atypical (7;19) translocation in acute myelomonocytic leukemia.

M E Sherer1, S Shekhter-Levin, J R Krause, R A Joyce, S M Gollin.   

Abstract

Chromosome studies were carried out after a 24-hour harvest of unstimulated bone marrow aspirate cell cultures from a 75-year-old male with a clinical diagnosis of acute myelomonocytic leukemia (FAB M4). Analysis of nine cells after trypsin-Giemsa banding (GTG) revealed two cell lines with a mosaic chromosome pattern, 46,XY/46,XY,t(7;19)(q22;p13.3). A review of the recent literature reveals one case of childhood ALL with a 46,XY/46,XY,t(7;19)(q11;q13) chromosome pattern [1] and a 46,XY,t(3q;11q),t(7q;19p),t(15;17)(q26;q22) in one patient with ANLL (FAB M3) [2]. The t(7;19)(q22;p13.3) seen in our case has not been reported as the sole specific clonal chromosome rearrangement in myeloid neoplasia. Interestingly, the plasminogen activator inhibitor type I, multi-drug resistance, and erythropoietin genes are located at band 7q22 and the insulin receptor gene is located at band 19p13.3. Both sites contain fragile site loci. The possible role of these fragile sites, genes, or other genes in the rearrangement can only be surmised.

Entities:  

Mesh:

Year:  1991        PMID: 1756494     DOI: 10.1016/0165-4608(91)90148-n

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

1.  Defining the borders of splenic marginal zone lymphoma: a multiparameter study.

Authors:  Scott D Dufresne; Raymond E Felgar; Rachel L Sargent; Urvashi Surti; Susanne M Gollin; Ellen D McPhail; James R Cook; Steven H Swerdlow
Journal:  Hum Pathol       Date:  2009-12-11       Impact factor: 3.466

2.  Morphologic and immunophenotypic characterization of a cell line derived from liver tissue with Epstein-Barr virus associated post-transplant lymphoproliferative disease.

Authors:  P S Randhawa; A Zeevi; C Alvares; S Gollin; R Agostini; E Yunis; S Saidman; L Contis; A J Demetris; M A Nalesnik
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-06       Impact factor: 2.416

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.